PER 1.22% 8.1¢ percheron therapeutics limited

For General Information, page-2412

  1. 2,947 Posts.
    lightbulb Created with Sketch. 479
    The science is hard to get one's head around for the average layperson imo -

    CAP 1002 and ATL 1102 are two different therapies for Duchenne muscular dystrophy (DMD), a genetic disorder that causes progressive muscle loss and premature death. CAP 1002 is a cell therapy that uses donor heart cells to reduce inflammation and muscle degeneration12. ATL 1102 is an antisense inhibitor that targets a protein involved in the fibrotic process in DMD

    Bottom line, I guess it will be a case of which therapy works best and who gets there first with runs on the board!  - as we all know, there are no guarantees of success in the Biotech space with everyone competing to be first past the post - just maybe ATL1102 will deliver the goods this time around for all concerned!

    GLTAH's
    .
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.1¢
Change
-0.001(1.22%)
Mkt cap ! $73.92M
Open High Low Value Volume
8.0¢ 8.2¢ 8.0¢ $20.79K 256.8K

Buyers (Bids)

No. Vol. Price($)
3 119742 7.9¢
 

Sellers (Offers)

Price($) Vol. No.
8.1¢ 43738 2
View Market Depth
Last trade - 11.48am 27/06/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.